How many stocks are there of ImmuPharma?
The current number of stocks of ImmuPharma is 302.91 M undefined.
ImmuPharma Stocks 2024
ImmuPharma Stocks
302.91 M
ImmuPharma Dividend yield
Ticker
IMM.L
ISIN
GB0033711010
WKN
A0BMC4
In 2024, ImmuPharma had 302.91 M outstanding stocks, a 0% change from the 302.91 M stocks in the previous year.
The ImmuPharma Stocks history
| YEAR | NUMBER OF STOCKS (undefined GBP) |
|---|---|
| 2024e | 302.91 |
| 2023e | 302.91 |
| 2022 | 302.91 |
| 2021 | 251.16 |
| 2020 | 200.18 |
| 2019 | 153.45 |
| 2018 | 138.84 |
| 2017 | 130.9 |
| 2016 | 117.34 |
| 2015 | 88.62 |
| 2014 | 83.6 |
| 2013 | 81.66 |
| 2012 | 81.53 |
| 2011 | 81.53 |
| 2010 | 81.17 |
| 2009 | 81.61 |
| 2008 | 81.84 |
| 2007 | 72.78 |
| 2006 | 68.39 |
| 2005 | 59.66 |
ImmuPharma Aktienanalyse
What does ImmuPharma do?
ImmuPharma PLC is a biopharmaceutical company specializing in the development of drugs for the treatment of autoimmune diseases and cancer. The company was founded in 1999 and is headquartered in London, England. ImmuPharma's history began with the discovery of a new peptide extracted from the trail of a snail. This substance has potent immunomodulatory potential and can inhibit the growth of certain tumor cells. ImmuPharma recognized the potential of this discovery and began developing a new drug based on this peptide. ImmuPharma's business model is to develop innovative drugs and license or sell them to large pharmaceutical companies. The company works closely with leading scientists and experts in drug development to ensure the efficacy and safety of its products. ImmuPharma has focused on two main areas: autoimmune diseases and cancer. Autoimmune diseases are conditions in which the immune system malfunctions and attacks the body. The autoimmune diseases that ImmuPharma targets include lupus erythematosus, rheumatoid arthritis, multiple sclerosis, and myasthenia gravis. ImmuPharma has also developed a drug called Lupuzor for the treatment of systemic lupus erythematosus (SLE). SLE is a severe autoimmune disease that causes inflammation and pain in various parts of the body. Lupuzor was developed as a first-in-class drug that regulates the immune system and reduces inflammation without compromising the body's normal defense function. In the field of cancer, ImmuPharma has also developed promising products that aim to inhibit tumor progression. The company has identified and tested a range of peptide- and protein-based drug candidates, including IPP-204106, which is used for the treatment of advanced prostate cancer. Last year, ImmuPharma also developed a new drug called Ureka for the treatment of urinary tract infections. Ureka is a bacterial toxin that specifically targets E. coli bacteria, which are the most common cause of urinary tract infections. In recent years, ImmuPharma has entered into several important partnerships to advance the development of its drugs. One partnership is with the Chinese company Avion Pharmaceuticals, which holds the marketing rights for Lupuzor in North America, Australia, and New Zealand. Another partnership is with the US company Orphan Reach, which supports the development and marketing of Ureka. Overall, ImmuPharma represents innovation and progress in drug development. The company is dedicated to a crucial purpose, seeking cures for those suffering from autoimmune diseases and cancer. Through a combination of scientific excellence and strategic partnerships, ImmuPharma has the potential to achieve significant therapeutic advancements and improve the lives of countless patients. ImmuPharma ist eines der beliebtesten Unternehmen auf Eulerpool.com.Stocks Details
Evaluating ImmuPharma's Shares Outstanding
ImmuPharma's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.
Year-to-Year Comparison
Tracking the changes in ImmuPharma’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.
Impact on Investments
For investors, understanding ImmuPharma’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.
Interpreting Changes in Shares Outstanding
Variances in ImmuPharma’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.
Frequently Asked Questions about ImmuPharma Stock
What does Number of Shares / OutstandingShares mean?
The outstanding shares (or issued shares) of ImmuPharma are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.
How has the number of shares of ImmuPharma evolved in recent years?
The number of shares of ImmuPharma has increased by 0% gestiegen compared to last year.
What does the number of shares mean for investors?
The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.
Why does the number of stocks fluctuate?
There are various factors that can lead to a change. ImmuPharma as a company can issue new shares, carry out stock splits or reverse splits.
Does the number of shares have an impact on the performance of ImmuPharma?
There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).
How much dividend does ImmuPharma pay?
Over the past 12 months, ImmuPharma paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, ImmuPharma is expected to pay a dividend of 0 GBP.
What is the dividend yield of ImmuPharma?
The current dividend yield of ImmuPharma is .
When does ImmuPharma pay dividends?
ImmuPharma pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of ImmuPharma?
ImmuPharma paid dividends every year for the past 0 years.
What is the dividend of ImmuPharma?
For the upcoming 12 months, dividends amounting to 0 GBP are expected. This corresponds to a dividend yield of 0 %.
In which sector is ImmuPharma located?
ImmuPharma is assigned to the 'Health' sector.
Wann musste ich die Aktien von ImmuPharma kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of ImmuPharma from 5/31/2024 amounting to 0 GBP, you needed to have the stock in your portfolio before the ex-date on 5/31/2024.
When did ImmuPharma pay the last dividend?
The last dividend was paid out on 5/31/2024.
What was the dividend of ImmuPharma in the year 2023?
In the year 2023, ImmuPharma distributed 0 GBP as dividends.
In which currency does ImmuPharma pay out the dividend?
The dividends of ImmuPharma are distributed in GBP.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von ImmuPharma
Our stock analysis for ImmuPharma Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of ImmuPharma Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
